Efficacy, safety, tolerability, and noninferiority phase 3 study of glucagon as a ready‐to‐use room temperature liquid stable formulation versus a lyophilised formulation for the biochemical recovery and symptomatic relief of insulin‐induced severe hypoglycaemia in adults with type 1 diabetes

TRP has received research funding (paid to university) from Zealand Pharma, AstraZeneca, Novo Nordisk and Sanofi and has received consulting fees from Adocia, Arecor, AstraZeneca, Eli Lilly, Novo Nordisk, Sanofi and The Longevity Laboratories. RA has received advisory fees from Sanofi, Novo Nordisk, Boehringer Ingelheim, Eli Lilly, HTL Strefa, Gilead, Merck and Xeris Pharmaceuticals and research funding from Novo Nordisk, AstraZeneca, Eli Lilly, Zealand, Xeris Pharmaceuticals, Medpace, Kowa, Insulet, Dexcom and Bayer. MPC has received research funding from Abbott Diabetes Care, Biolinq, Dexcom, Medtronic, Novo Nordisk, Eli Lilly, Helixmith, Pfizer, Novabio, GraphWear, Ascensia and Abbott Point of Care. BB and his employer, Atlanta Diabetes Associates, has received grant support from Xeris Pharmaceuticals, and BB has received speaker fees from Xeris Pharmaceuticals. KJ and VC are employees of Xeris Pharmaceuticals. The peer review history for this article is available at https://publons.com/publon/10.1111/dom.14699. Data are available upon reasonable request. All data relevant to the study are included in the article or as supplementary information. Appendix S1 Supporting Information Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.